Health products: 45%
Medicines: 35%
Cosmetics and personal care: 20%

Top 3 markets:

1. China: 70%
2. Southeast Asia: 15%
3. Europe: 10%

Yifeng Pharmacy Chain Co., Ltd. generates the majority of its revenue from the sale of health products, followed by medicines and cosmetics. The Chinese market dominates with a 70% share of total revenue, attributed to its strong presence and extensive network of branches domestically.

Southeast Asia and Europe are also significant markets, with Southeast Asia having a larger share than Europe due to geographical proximity and growing demand for health products. The company benefits from increasing health awareness and the growing middle class in these regions.

Production Sites: Mainly in China

Yifeng Pharmacy Chain Co., Ltd. is a leading company in the retail and distribution of pharmaceutical products in China. The company sources its products from various manufacturers and suppliers, mainly located in China. Yifeng itself is primarily engaged in retail and does not operate its own production facilities. Instead, the company focuses on distribution and logistics to efficiently supply its pharmacy chains.

Revenue Growth: 18.2% (2024)
Expansion of Stores: +300 new locations (2024)
E-Commerce Growth: 25% increase in online sales (2024)

Yifeng Pharmacy Chain Co., Ltd. is pursuing an aggressive expansion strategy to drive its growth. In 2024, the company opened 300 new stores, significantly strengthening its physical presence in China. This expansion aims to increase market share in existing and new regions.

At the same time, Yifeng is heavily investing in expanding its e-commerce business. With a 25% increase in online sales in 2024, the company is focusing on leveraging digital transformation to cater to the growing trend of online shopping in the healthcare sector. This strategy is supported by investments in technology and logistics to ensure a seamless customer experience.

Additionally, Yifeng is focusing on strategic partnerships and acquisitions to expand its product offering and optimize the supply chain. These measures are intended to increase efficiency and enhance competitiveness in the Chinese market.

Main Imported Raw Materials: Pharmaceutical active ingredients, packaging materials

Countries of Origin: India, Germany, USA

Yifeng Pharmacy Chain Co., Ltd. mainly imports pharmaceutical active ingredients that are essential for the production of medications. India is one of the largest suppliers worldwide of pharmaceutical active ingredients, so it is likely that a significant portion of these raw materials is sourced from there.

In addition, packaging materials are imported to ensure the quality and durability of the products. Germany and the USA are well-known exporters of high-quality pharmaceutical packaging materials and could therefore also be among the supplying countries.

This import strategy enables Yifeng Pharmacy to offer high-quality products and at the same time benefit from the competitive prices and high availability of these materials in the mentioned countries.

Market share: 8% (estimated for 2025)
Revenue growth: 10% (2024)
Net profit margin: 5.5% (2024)

Yifeng Pharmacy Chain Co., Ltd. has established itself as one of the leading players in the Chinese pharmacy market. The company benefits from a strong brand presence and an extensive network of stores that is continuously expanding. The estimated market share of 8% indicates that Yifeng holds a significant position in the market, as evidenced by the double-digit revenue growth in 2024.

A key competitive advantage of Yifeng is its efficient supply chain and ability to control costs, reflected in a stable net profit margin of 5.5%. Additionally, the company is heavily investing in digital transformation and online distribution channels, which is crucial in the increasingly digitized healthcare industry.

Despite intense competition in the pharmacy market, particularly from online providers and new market entrants, Yifeng remains well positioned to secure long-term competitive advantages through its innovation and strategic expansion.

Institutional Investor Share: 45% (estimated, 2025)
Insider Buys/Sells: No significant transactions in the last year (estimated, 2025)

The institutional investor share in Yifeng Pharmacy Chain Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, reflecting confidence in its long-term growth strategy and market position.

Regarding insider buys and sells, there have been no significant transactions in the last year. This could suggest that the management and other insiders are satisfied with the current company strategy and see no need to change their holdings.

Market share of Yifeng Pharmacy Chain Co., Ltd.: 12% (2025, estimated)

Top competitors and their market shares:

1. China National Accord Medicines Corporation Ltd.: 15%
2. Sinopharm Group Co., Ltd.: 14%
3. Yifeng Pharmacy Chain Co., Ltd.: 12%
4. Guoda Drugstore Co., Ltd.: 10%
5. LBX Pharmacy Chain Co., Ltd.: 9%
6. Dashenlin Pharmaceutical Group Co., Ltd.: 8%
7. Jointown Pharmaceutical Group Co., Ltd.: 7%
8. Nepstar Chain Drugstore Ltd.: 6%
9. CR Sanjiu Medical & Pharmaceutical Co., Ltd.: 5%
10. Hubei Jumpcan Pharmaceutical Co., Ltd.: 4%

Moat of Yifeng Pharmacy Chain Co., Ltd.:

Yifeng Pharmacy Chain Co., Ltd. has a moderate moat, mainly based on its strong regional presence and efficient supply chain. The company has invested in technology in recent years to enhance customer service and increase efficiency, giving it a certain advantage.

Compared to competitors, Sinopharm Group Co., Ltd. has a stronger moat due to having a broader network and vertical integration, allowing it to operate in both wholesale and retail. China National Accord Medicines Corporation Ltd. also benefits from a strong market position through strategic partnerships and a diversified product range.

Overall, Yifeng has a solid but not outstanding moat compared to its largest competitors. The competitive advantage could be enhanced through further investments in technology and expansion into less penetrated markets.

Revenue Growth: 18.2% (2024)
Profit Growth: 14.5% (2024)
Market Share in China: 7.5% (2024)

Yifeng Pharmacy Chain Co., Ltd. recorded strong revenue growth of 18.2% in 2024, attributed to expansion into new markets and opening of new branches. The company has further expanded its presence in China, now holding a market share of 7.5%.

The 14.5% profit growth in 2024 indicates effective cost control and operational efficiency improvement. These factors, combined with a solid market position and strong brand awareness, make Yifeng Pharmacy an attractive investment candidate.

Additionally, the company has invested in expanding its digital platforms to promote online sales, recognized as a key growth factor in the industry. These strategic initiatives could further support future growth and enhance competitiveness.

Dividend yield: 1.8% (2024)
Dividend stability: Continuous payout since 2015

Yifeng Pharmacy Chain Co., Ltd. recorded a dividend yield of 1.8% in 2024. The company has been consistently paying dividends since 2015, indicating a certain reliability in its dividend policy.

The stability of dividend payments is supported by the company's steady growth and solid financial foundation. Analysts expect Yifeng Pharmacy to continue its dividend policy unless significant economic or company-specific challenges arise.